Tasly Pharmaceutical Group
CompanyChina
Tasly Pharmaceutical Group develops one asset, in phase 2 (mesenchymal stem cells in COVID-19 pneumonia). Mostly cell therapy acting on inflammation and stem cell maintenance; based in China.
- Assets
- 1
- Furthest
- Phase 2
- Trials
- 1
- Signals
- 0
Pipeline
1Umbilical cord-derived mesenchymal stem cells for tissue repair and immunomodulation
Phase 2Cell therapyInflammationStem cell maintenanceCOVID-19 pneumoniaHuntington's disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials1
- Signals2
- Similar companies6
Updated 7 Oct 2026 · 28 sources